INTRODUCTION
In the heart, muscle contraction is triggered by the release of Ca 2 + from the SR (sarcoplasmic reticulum) [1, 2] . Once triggered, SR Ca 2 + release is rapidly terminated to ensure proper EC (excitation-contraction) coupling and muscle relaxation that are fundamental to the cardiac cycle [3] [4] [5] [6] . It is well established that the initiation of SR Ca 2 + release results from the activation of the RyR2 (cardiac ryanodine receptor) Ca 2 + -release channel via a mechanism known as Ca 2 + -induced Ca 2 + release [1, 2] . However, the molecular mechanism underlying the termination of SR Ca 2 + release is largely unknown [3] [4] [5] . SR Ca 2 + -release termination probably results from the inactivation of RyR2, but how RyR2 is inactivated is unclear. An increasing body of evidence suggests that a decrease in SR luminal Ca 2 + level following SR Ca 2 + release plays an important role in the inactivation of RyR2 and the termination of Ca 2 + release [5, [7] [8] [9] [10] [11] [12] [13] . Important insights into the role of SR Ca 2 + depletion in Ca 2 + -release termination have previously been revealed using SR luminal Ca 2 + -sensing dyes, such as fluo-5N [12] [13] [14] [15] . By directly monitoring the SR luminal Ca 2 + dynamics in isolated cardiomyocytes, Zima et al. [13] showed that Ca 2 + sparks or global Ca 2 + transients terminated when the SR Ca 2 + content decreases to a threshold level, called the termination threshold. These observations suggest that SR luminal Ca 2 + depletion is a major signal for Ca 2 + -release termination [5] . Interestingly, the termination threshold for Ca 2 + sparks or global Ca 2 + transients (∼60 % of the resting SR Ca 2 + level) was found to be independent of the initial SR Ca 2 + load, the magnitude of Ca 2 + -release flux or the level of cytosolic Ca 2 + [13]. We have also shown that spontaneous Ca 2 + release in HEK (human embryonic kidney)-293 cells expressing RyR2 displays a termination threshold of ∼57 % [16] . Hence, the phenomenon of Ca 2 + -release termination is not unique to cardiac cells. It probably reflects the intrinsic properties of RyR2.
As with the activation of SR Ca 2 + release, the termination of SR Ca 2 + release is likely to be subjected to modulation by various conditions and factors. Indeed, the threshold for Ca 2 + -release termination is altered in disease states. For instance, in failing cardiomyocytes, the termination threshold was reduced, leading to delayed termination of Ca 2 + release [17] . We have recently shown that RyR2 mutations associated with cardiomyopathies altered the termination threshold [16] . The termination threshold is also modulated by physiological and pharmacological ligands. It has recently been shown that isoproterenol increases the termination threshold (i.e. facilitates the termination of Ca 2 + release) [18] . On the other hand, caffeine was found to reduce the termination threshold, resulting in delayed Ca 2 + -release termination [17, 19] . RyR2 is regulated by a number of protein effectors such as CaM (calmodulin) [20] [21] [22] . Whether RyR2-interacting proteins Abbreviations used: CaM, calmodulin; C-lobe, C-terminal lobe; CPVT, catecholaminergic polymorphic ventricular tachycardia; ER, endoplasmic reticulum; fura 2/AM, fura 2 acetoxymethyl ester; HEK, human embryonic kidney; KRH, Krebs-Ringer-Hepes; N-Lobe, N-terminal lobe; RyR2, cardiac ryanodine receptor; SOICR, store-overload-induced Ca 2 + release; SR, sarcoplasmic reticulum; WT, wild-type. 1 Present address: Taihe Hospital Affiliated Hosptial of Hubei University of Medicine, Hubei, People's Republic of China 2 To whom correspondence should be addressed (email swchen@ucalgary.ca).
also modulate the threshold for Ca 2 + -release termination has yet to be determined. CaM has been shown to inhibit the Ca 2 + -dependent activation of single RyR2 channels [22] . CaM binds to a region in RyR2 encompassing residues 3583-3603. Deletion of these residues abolishes CaM binding to RyR2 and the CaMdependent inhibition of single RyR2 channels [21] . Interestingly, point mutations in this region either abolish both the binding and inhibitory action of CaM or only eliminate the inhibitory action of CaM without affecting CaM binding [21] . Importantly, a triple mutation in this region (W3587A/L3591D/F3603A) which abolishes CaM binding to RyR2 causes severe heart failure, cardiomyopathies and early death in mice [23] . Neonatal cardiomyocytes isolated from the RyR2 triple-mutant mice exhibited prolonged Ca 2 + transients, suggesting altered Ca 2 + -release termination [23] 
MATERIALS AND METHODS

Site-directed mutagenesis
The cloning and construction of the 15-kb full-length cDNA encoding the mouse cardiac RyR2 has been described previously [25] . The RyR2 deletion, Del-3583-3603, and the point mutations W3587A, L3591D, F3603A and W3587A/L3591D/F3603A were constructed according to the previously described PCR-mediated overlap extension method [26] . A fragment containing Del-3583-3603, W3587A, L3591D, F3603A or W3587A/L3591D/F3603A was produced by PCR and subcloned into BsiWI (8864)-NotI (vector) RyR2 WT DNA fragment using AgeI (10370) and SacII (11202). The fragment containing the deletion or mutations was then subcloned to the full-length RyR2 in pcDNA3 or pcDNA5 using BsiWI (8864) and NotI (vector). Ca 2 + -binding-deficient CaM mutations, CaM(1, 2), CaM (3, 4) or CaM(1-4), in which two or all of the asparagine residues (residues 20, 56, 93 and 129) were mutated to alanine, were also generated using the PCRmediated overlap extension method. The sequences of all PCR fragments were verified by DNA sequencing analysis.
Generation of stable inducible HEK-293 cell lines
Stable inducible HEK-293 cell lines expressing RyR2 WT, deletion and mutations were generated using the Flp-In TREx Core Kit from Invitrogen. Briefly, Flp-In T-REx-293 cells were co-transfected with the inducible expression vector pcDNA5/FRT/TO containing the mutant cDNAs and the pOG44 vector encoding the Flp recombinase at a ratio of 1:5 using the Ca 2 + phosphate precipitation method. The transfected cells were washed with PBS 24 h after transfection followed by a change into fresh medium for 24 h. The cells were then washed again with PBS, harvested and plated on to new dishes. After the cells had attached (∼4 h), the growth medium was replaced with a selection medium containing 200 μg/ml hygromycin (Invitrogen). The selection medium was changed every 3-4 days until the desired number of cells was grown. The hygromycin-resistant cells were pooled, divided into aliquots and stored at − 80
• C. These positive cells are believed to be isogenic, because the integration of RyR2 cDNA is mediated by the Flp recombinase at a single FRT site. Luminal Ca 2 + in HEK-293 cells expressing RyR2 WT or mutations were measured using single-cell Ca 2 + imaging and the Ca 2 + -sensitive FRET-based cameleon protein D1ER as described previously [29] . The cells were grown to 95 % confluency in a 75 cm 2 flask, split with PBS, and plated on to 100-mmdiameter tissue culture dishes at ∼10 % confluence 18-20 h before transfection with D1ER or co-transfection with D1ER and CaM(WT), CaM(1, 2), CaM (3, 4) or CaM(1-4) cDNA. At 24 h after transfection, an induction medium containing 1 μg/ml tetracycline (Sigma) was applied to induce the expression of RyR2 in these cells. After induction for ∼22 h, the cells were perfused continuously with KRH buffer containing various concentrations of CaCl 2 (0-2 mM) and tetracaine (1 mM) or caffeine (20 mM) at room temperature. Images were captured by a QuantEM 512SC camera every 2 s using the NIS-Elements AR software. Cells were excited at 430 nm, and the emission was split into 465-and 535-nm beams by a dual-view device (Photometrics) placed in a Nikon eclipse Ti microscope. D1ER signals were determined from the ratios of the emissions at 535 + − 30 nm (YFP) and 465 + − 30 nm (CFP).
Statistical analysis
All values shown are means + − S.E.M. unless indicated otherwise. To test for differences between groups, we used Student's t test (two-tailed) or one-way ANOVA with post-hoc test. A P value of <0.05 was considered to be statistically significant. To assess the effect of CaM on the termination of Ca 2 + release, we co-transfected HEK-293 cells expressing WT RyR2 with CaM and a FRET-based ER luminal Ca 2 + -sensing protein D1ER [24] . The ER luminal Ca 2 + dynamics in transfected HEK-293 cells was then monitored using single-cell FRET imaging as described previously [16, 19, 29, 30] . As shown in Figure 1 oscillations in HEK-293 cells expressing WT RyR2, also known as SOICR [27, 28] (observed as downward deflections of the FRET signal). SOICR occurred when the ER luminal Ca 2 + increased to a threshold level (the SOICR activation threshold, F SOICR ), and terminated when the ER luminal Ca 2 + fell to another threshold level (the SOICR termination threshold, F termi ) ( Figure 1A ). This SOICR in WT RyR2-expressing HEK-293 cells displayed an activation threshold of 93 + − 0.5 % store capacity and a termination threshold of 58 + − 0.7 % store capacity. Interestingly, a termination threshold of ∼60 % was observed in cardiomyocytes [13] . Thus Ca 2 + release in both cardiomyocytes and HEK-293 cells terminates before the store is completely depleted. It should be noted that SOICR did not occur in control HEK-293 cells expressing no RyR2, and that SOICR was not affected by the IP 3 R (inositol 1,4,5-trisphosphate receptor) inhibitor xestospongin C [16] , indicating that SOICR in RyR2-expressing HEK-293 cells is mediated by RyR2.
RESULTS
CaM increases the luminal
The effect of CaM on SOICR is shown in Figure 1 (B). Coexpression of CaM in RyR2-expressing HEK-293 cells had no significant effect on the activation threshold ( Figure 1D ), but it significantly increased the termination threshold (65 + − 1.1 %) as compared with the control (P < 0.001) ( Figure 1E ). As a result, the fractional Ca 2 + release during SOICR (activation threshold − termination threshold) was significantly reduced in HEK-293 cells transfected with CaM (29 + − 0.7 %) than in control cells (36 + − 0.9 %) (P < 0.001) ( Figure 1F ). There were no significant differences in the store capacity (F max − F min ) between the control and the CaM-transfected cells ( Figure 1G ). The frequency of Ca 2 + oscillation in CaM-transfected cells (0.89 + − 0.02 event/min) is slightly higher than that in control cells (0.78 + − 0.04 event/min), but the significance of this difference is marginal (P = 0.05). It is important to note that the frequency of Ca 2 + oscillation depends not only on the activity of RyR2, but also on store Ca 2 + refilling, which is influenced by a number of factors, such as Ca 2 + influx, Ca 2 + uptake or Ca 2 + buffering. It is also important to note that the D1ER probe was not saturated in HEK-293 cells (results not shown), consistent with that reported previously [31] . Thus the effect of CaM is to terminate Ca The activation threshold (D) and termination threshold (E) were determined using the equations shown in (A). F SOICR indicates the FRET level at which SOICR occurs, whereas F termi represents the FRET level at which SOICR terminates. The fractional Ca 2 + release (F) was calculated by subtracting the termination threshold from the activation threshold. The maximum FRET signal F max is defined as the FRET level after tetracaine treatment. The minimum FRET signal F min is defined as the FRET level after caffeine treatment. The store capacity (F) was calculated by subtracting F min from F max . Data shown are means + − S.E.M. (n = 4-13) (*P < 0.001 compared with the control). mutated [32] . As shown in Figure 1 (C), CaM(1-4) significantly reduced the termination threshold (49 + − 2.4 %) as compared with the control (P < 0.001) ( Figure 1E ), but it had no effect on the activation threshold ( Figure 1D ). As a result, the fractional Ca 2 + release was significantly increased in HEK-293 cells transfected with CaM(1-4) (44 + − 2.7 %) (P < 0.001) ( Figure 1F ). Thus in contrast with CaM(WT), the Ca 2 + -binding deficient CaM(1-4) mutant inhibited Ca 2 + -release termination, probably by suppressing the effect of endogenous CaM. It should be noted that both apoCaM and Ca 2 + -CaM are able to bind RyR2 [22] . Thus these observations suggest that Ca 2 + binding to CaM is required for its action on Ca 2 + -release termination. To further dissect the importance of Ca 2 + binding to the N-lobe (N-terminal lobe) and C-lobe of CaM in mediating the effects of CaM on Ca 2 + -release termination, we took advantage of the Ca 2 + -binding mutants of CaM, CaM(1, 2), in which the two Ca 2 + -binding sites in the N-lobe were mutated, and CaM (3, 4) , in which the two Ca 2 + -binding sites in the C-lobe were mutated. As shown in Figure 2 , CaM(1, 2) increased the termination threshold and fractional Ca 2 + release in HEK-293 cells (Figures 2A and  2D ), an effect similar to that of CaM(WT) ( Figure 1B ). On the other hand, CaM(3, 4) reduced the termination threshold and fractional Ca 2 + release ( Figures 2D and 2E ), an effect similar to that of CaM(1-4) ( Figure 1C ). Neither CaM(1, 2) nor CaM(3, 4) altered the activation threshold ( Figure 2C ), similar to CaM(WT) or CaM (1-4) . Collectively, these data suggest that Ca 2 + binding to the C-lobe, but not to the N-lobe, is critical for CaM-facilitated termination of Ca 2 + release. To maximize the co-expression of RyR2, CaM and the luminal Ca 2 + sensor protein D1ER, we used an inducible stable HEK-293 cell line that expresses RyR2. We transfected these RyR2-expressing cells with D1ER and CaM. Only HEK-293 cells that were both fluorescently labelled (i.e. transfected with D1ER) and responded to caffeine (i.e. expressing RyR2) were used for analysis. Thus all cells analysed expressed both RyR2 and D1ER. However, it is possible that some of the RyR2-and D1ER-positive cells may not have been transfected with CaM WT or mutants. Therefore the effect of CaM WT and mutations on SOICR would have been underestimated. release by binding to RyR2, removal of the CaM-binding site in RyR2 should abolish CaM-dependent facilitation of Ca 2 + -release termination. Consistent with this view, we found that deletion of the CaM-binding site (residues 3583-3603) in RyR2 significantly lowered the termination threshold (32 + − 1.3 %) (P < 0.001) ( Figures 3A and 3E ), but had no effect on the activation threshold ( Figures 3A and 3D) . As a result, the fractional Ca 2 + release (62 + − 1.0 %) in these cells was significantly increased (P < 0.001) ( Figure 3F ures 3B-3F). Thus the termination or activation of Ca 2 + release in HEK-293 cells expressing the CaM-binding mutant of RyR2 was no longer sensitive to modulation by CaM(WT) or CaM(1-4). These data are consistent with the notion that CaM-facilitated termination of Ca 2 + release requires the CaM-binding site in RyR2.
Effect on Ca 2 + release termination of mutations in the CaM-binding site of RyR2 that exert different effects on CaM binding
Meissner and co-workers have reported that a triple mutation, W3587A/L3591D/F3603A, in the CaM-binding domain of RyR2 completely abolished CaM binding to and CaM-dependent inhibition of RyR2, whereas single point mutations W3587A and L3591D eliminated the inhibitory action of CaM with partial or no effect on CaM binding [21] . To determine whether these mutations with different effects on CaM binding affect Ca 2 + -release termination to different extents, we generated HEK-293 cell lines that express each of these mutations and determined their termination and activation thresholds. As shown in Figure 4 , the triple RyR2 mutation (W3587A/L3591D/F3603A) markedly reduced the termination threshold and increased the fractional Ca 2 + release, similar to the effect of the deletion mutant RyR2 Del-3583-3603. Interestingly, single RyR2 mutations (W3587A and L3591D) were also able to reduce the termination threshold and increase the fractional Ca 2 + release to an extent similar to that seen with the triple mutation (W3587A/L3591D/F3603A). Note that neither of these mutations affected the activation threshold. Thus these RyR2 mutations all significantly reduce the termination threshold for Ca 2 + release regardless of whether or not they affect CaM binding to RyR2. These data suggest that the CaM-binding domain of RyR2 is involved not only in binding CaM, but also in mediating the action of CaM in the termination of Ca 2 + release.
Mutation F3603A in the CaM-binding region of RyR2 alters both the activation and termination of Ca 2 + release Figure 5 shows the impact of the F3603A mutation in the CaMbinding site of RyR2 on SOICR. Unlike the triple mutation and other single mutations (W3587A and L3591D), the F3603A mutation diminished SOICR. Elevating extracellular Ca 2 + from 0 to 2 mM induced SOICR in HEK-293 cells expressing WT RyR2 ( Figure 5A ), but not in HEK-293 cells expressing the F3603A mutant ( Figure 5B ). However, SOICR could be induced in these F3603A-expressing cells by adding caffeine (1 mM) to the perfusate ( Figure 5B ). Since caffeine is known to induce SOICR by decreasing the activation threshold [19] , the rescue of SOICR by caffeine in the F3603A cells suggests that the F3603A mutation may suppress SOICR by increasing the activation threshold. To test this possibility, we induced SOICR in both RyR2-WT and F3603A-expressing HEK-293 cells by caffeine (1 mM) and compared their SOICR properties under the same conditions. In the presence of 1 mM caffeine, WT RyR2-expressing cells exhibited an activation threshold of 70 + − 2.3 % store capacity ( Figures 5A and 5C ), whereas the F3603A mutantexpressing cells displayed a significantly increased activation threshold (88 + − 0.9 %, P < 0.01) compared with the WT cells ( Figures 5B and 5C ). With an increased activation threshold, the F3603A mutation would be expected to decrease the propensity for SOICR. Indeed, single-cell cytosolic Ca 2 + imaging revealed that only a very small fraction of F3603A mutant-expressing HEK-293 cells displayed Ca 2 + oscillations upon elevation of extracellular Ca 2 + , which is markedly different from WT RyR2 cells (Figure 6 ). Furthermore, the F3603A mutation also significantly decreased the termination threshold (27 + − 2.0 % compared with 37 + − 1.1 % in WT, P < 0.01) ( Figure 5D ), and increased the fractional Ca 2 + release (61 + − 2.4 % compared with 33 + − 1.3 % in WT, P < 0.01) ( Figure 5E ). Thus the F3603A mutation affects not only the termination, but also the activation of Ca 2 + release, suggesting that the CaM-binding site of RyR2 is important for both the activation and termination of Ca 2 + release.
DISCUSSION
It has previously been shown that Ca 2 + release in cardiac cells terminates when the SR Ca 2 + content depletes to a threshold level (A and B) . The fractional Ca 2 + release (E) was calculated by subtracting the termination threshold from the activation threshold with 1 mM caffeine. The store capacity (F) was calculated by subtracting F min from F max . Data shown are means + − S.E.M. (n = 4-5) (*P < 0.01 compared with WT).
(the termination threshold) [13] . Importantly, this termination threshold is altered in diseases and modulated by physiological and pharmacological ligands [17] [18] [19] . These findings raise an intriguing and important question of whether CaM also regulates Ca 2 + -release termination by altering the termination threshold. [15] . However, it is important to note that Ca 2 + -release termination is still present in CASQ2-deficient cardiomyocytes [35] , indicating that CASQ2-mediated termination of Ca 2 + release is not the only mechanism of Ca 2 + -release termination. It is also important to know that HEK-293 cells lack muscle-specific proteins such as CASQ2, triadin and junctin. Hence it will be of interest and importance to determine whether these proteins modulate the threshold for Ca 2 + -release termination. It is also possible that reduced SR luminal Ca 2 + could desensitize RyR2 via its luminal Ca 2 + -regulatory sites [34] . Alternatively, long-range allosteric conformational changes in RyR2 induced by the reduced SR luminal Ca 2 + content as a consequence of Ca 2 + release may contribute to the CaM-dependent facilitation of release termination in addition to elevated cytosolic Ca 2 + . Therefore it is likely that multiple mechanisms are involved in the termination of Ca 2 + release. Further detailed and systematic studies will be required to fully understand the mechanism of Ca 2 + -release termination.
Role of the CaM-binding domain of RyR2 in Ca 2 + -release activation and termination
The CaM-binding site in RyR2 has been localized to residues 3583-3603. Deletion of this sequence or a triple mutation (W3587A/L3591D/F3603A) within this region abolishes both CaM binding to RyR2 and the inhibitory effect of CaM on single RyR2 channels [21] . Interestingly, single mutations, W3587A, L3591D and F3603A, partially affect CaM binding, but eliminate the inhibitory action of CaM. It was suggested that the CaMbinding domain plays a role not only in binding with CaM, but also in transducing the binding of CaM to a functional effect on RyR2 via interactions with other domains of RyR2 [21] . Consistent with this view, we found that deletion of the CaM-binding site and the triple and single mutations, regardless of whether they eliminate CaM binding or not, all abolished the action of CaM in facilitating Ca 2 + -release termination. Furthermore, we showed that the point mutation F3603A also affected the activation of spontaneous Ca 2 + release by increasing the activation threshold, thereby reducing the propensity for SOICR, in addition to its impact on the termination threshold. Therefore the CaM-binding domain of RyR2 is an important determinant of both the activation and termination of Ca 2 + release, and the function of this domain is likely to be modulated by CaM in a Ca 2 + -dependent manner.
Role of CaM-RyR2 interactions in the pathogenesis of cardiomyopathies and CPVT (catecholaminergic polymorphic ventricular tachycardia)
Naturally occurring RyR2 mutations have been linked not only to cardiac arrhythmias and sudden death, but also to cardiomyopathies [36] . We have previously shown that RyR2 mutations linked to CPVT reduce the activation threshold for SOICR [27] [28] [29] 37] . Recently, we have demonstrated that RyR2 mutations associated with both cardiac arrhythmias and cardiomyopathies reduce both the activation and termination thresholds for SOICR, and suggested that abnormal termination of Ca 2 + release can lead to cardiomyopathies [16] . Considering the finding that CaM modulates the termination threshold for Ca 2 + release, an altered CaM-RyR2 interaction may be involved in cardiomyopathies. Consistent with this view, knock-in mice harbouring a triple mutation (W3587A/L3591D/F3603A) in RyR2 that abolishes CaM binding and the action of CaM in Ca 2 + -release termination developed severe cardiomyopathy [23] . A relatively modest cardiomyopathy was also observed in knockin mice expressing the RyR2 L3591D mutation that affects Ca 2 + -release termination [38] .
An altered CaM-RyR2 interaction may also be involved in the pathogenesis of CPVT. A CPVT-associated RyR2 mutation, R2474S, has been shown to affect interdomain interactions, which in turn alter CaM-RyR2 interactions upon protein kinase A-dependent phosphorylation of RyR2, leading to enhanced spontaneous Ca 2 + release [39] . A defective CaM-RyR2 interaction may result from mutations in CaM. Recently, genome-wide linkage analysis and DNA sequencing have linked the calmodulin gene (CAML1) to a dominantly inherited form of CPVT-like cardiac arrhythmia, and identified several disease-associated CaM mutations [40] . It is unknown, however, how these CaM mutations cause CPVT-like arrhythmias. Further investigations will be required to assess whether these disease-associated CaM mutations affect the termination and/or activation threshold for RyR2-mediated Ca 2 + release. A potential explanation, on the basis of the results of the present study, is that disease-linked CaM mutations may reduce the termination threshold for RyR2-mediated Ca 2 + release. A reduced termination threshold would increase the fractional Ca 2 + release and thus the amplitude of spontaneous Ca 2 + release under conditions of SR Ca 2 + overload, which would in turn enhance the propensity for spontaneous Ca 2 + -release-induced DADs (delayed afterdepolarizations) and triggered activities. Therefore an abnormal CaM-RyR2 interaction may be, in part, attributable to the pathogenesis of cardiomyopathies and CPVT.
In summary, the present study demonstrates for the first time that CaM modulates the termination threshold for RyR2-mediated Ca 2 + release, and that the CaM-binding domain of RyR2 is an important determinant of Ca 2 + -release termination and activation. A defective CaM-RyR2 interaction may lead to cardiomyopathies and cardiac arrhythmias.
